View Older Stories View More Recent Stories
-
Morgan Stanley Assumes Kymera Therapeutics (KYMR) at Overweight
-
Stifel Defending Kymera Therapeutics (KYMR): 'We see any weakness from today's news as a buying opportunity'
-
Kymera Therapeutics (KYMR) PT Raised to $54 at BofA Securities
-
Kymera Therapeutics (KYMR) PT Raised to $60 at H.C. Wainwright
-
Kymera Therapeutics (KYMR) announces $250 million public offering
-
Kymera Therapeutics (KYMR) PT Lowered to $70 at Brookline Capital Markets
-
Kymera Therapeutics (KYMR) PT Lowered to $64 at Jefferies
-
Stifel says buy Kymera Therapeutics (KYMR) on today's weakness
-
Leerink Partners Reiterates Outperform Rating on Kymera Therapeutics (KYMR)
-
Kymera Therapeutics (KYMR) Announces Sanofi IRAK4 Collaboration Update
-
Gilead Sciences (GILD) and Kymera Therapeutics (KYMR) Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
-
UBS Reiterates Buy Rating on Kymera Therapeutics (KYMR)
-
Kymera Therapeutics (KYMR) PT Raised to $68 at Stifel
-
H.C. Wainwright Reiterates Buy Rating on Kymera Therapeutics (KYMR)
-
Wells Fargo Reiterates Overweight Rating on Kymera Therapeutics (KYMR)
-
B.Riley Upgrades Kymera Therapeutics (KYMR) to Buy
-
Morgan Stanley Upgrades Kymera Therapeutics (KYMR) to Overweight
-
Truist Securities Reiterates Buy Rating on Kymera Therapeutics (KYMR) Following Data
-
Kymera Therapeutics (KYMR) PT Raised to $60 at Citi
-
BofA Securities Upgrades Kymera Therapeutics (KYMR) to Buy
-
Stifel Reiterates Buy Rating on Kymera Therapeutics (KYMR) Following Data
-
Citi Reiterates Buy Rating on Kymera Therapeutics (KYMR)
-
Kymera Therapeutics (KYMR) Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
-
Kymera Therapeutics (KYMR) to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025
-
Stifel Resumes Kymera Therapeutics (KYMR) at Buy
-
Kymera Therapeutics (KYMR) Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference
-
Truist Securities 'Incrementally Positive' on Kymera Therapeutics (KYMR)
-
Kymera Therapeutics (KYMR) PT Lowered to $55 at BTIG
-
Truist Securities 'Incrementally Positive' on Kymera Therapeutics (KYMR) Following Q1 Update
-
Kymera Therapeutics (KYMR) Tops Q1 EPS by 7c
-
Kymera Therapeutics (KYMR) Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases
-
Truist Securities Reiterates Buy Rating on Kymera Therapeutics (KYMR) ahead of June readout
-
Kymera Therapeutics (KYMR) Appoints Noah Goodman as Chief Business Officer
-
Truist Securities Reiterates Buy Rating on Kymera Therapeutics (KYMR)
-
UBS Reiterates Buy Rating on Kymera Therapeutics (KYMR)
-
Kymera Therapeutics (KYMR) PT Lowered to $54 at H.C. Wainwright
-
Kymera Therapeutics (KYMR) Misses Q4 EPS by 11c
-
NAYA Biosciences (NAYA) nominates new Board members
-
Kymera Therapeutics (KYMR) Outlines Key 2025 Objectives and Strategy
-
Stifel Reiterates Buy Rating on Kymera Therapeutics (KYMR) Amid 'Bold Strategy'
-
BMO Capital Starts Kymera Therapeutics (KYMR) at Market Perform
-
Wells Fargo Upgrades Kymera Therapeutics (KYMR) to Overweight
-
Kymera Therapeutics (KYMR) PT Raised to $56 at Stifel
-
Kymera Therapeutics (KYMR) PT Raised to $41 at B.Riley
-
Kymera Therapeutics (KYMR) PT Raised to $59 at Jefferies
-
Kymera Therapeutics (KYMR) Tops Q3 EPS by 1c
-
Kymera Therapeutics (KYMR) Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader
-
Kymera Therapeutics (KYMR) PT Raised to $56 at Oppenheimer
-
Kymera Therapeutics (KYMR) Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress
-
Leerink Partners Assumes Kymera Therapeutics (KYMR) at Outperform, 'We have a more cautious view on KT-474'
